Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole + amoxicillin dual therapy versus bismuth-based triple therapy for first-line Helicobacter pylori eradication
ChiCTR-IPR-17014099Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esomeprazole, amoxicillin and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Eradication rate. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
esomeprazoleamoxicillinbismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR-IPR-17014099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17014099.